Editorial: Emerging therapies for metabolic bone diseases

• by Alberto Falchetti, Luigi Gennari

• July 17, 2026

Beyond Bone Density: How Fracture Risk Is Changing Osteoporosis Management

As osteoporosis treatment continues to evolve, clinicians are moving beyond bone mineral density scores alone and placing greater emphasis on fracture risk when making therapeutic decisions

• by

• July 8, 2026

• 7 min

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

• by Kathryn Wighton

• June 11, 2026

• 2 min

Naringin and denosumab ameliorate osteoporosis and suppress the aldosterone-MR/SGK1 signaling axis by modulating the bone-kidney interorgan communication in Orchiectomized rats

• by Shishuo Xiong, Guoying Wu, Yelin Zhong, Rong Xiang, Yukai Zhang, Haiwei Guo, Zehua Guo, Wenhao Lu, Qing Lan, Yongzhen Chen, Ying Li

• June 30, 2026